Pharmacokinetic analyses: ANOVA comparison of geometric least-squares-mean ratios (90% confidence intervals)
| Analyte Parameter | Concomitant Administration | 1-Hour Separation | 2-Hour Separation | 3-Hour Separation |
|---|---|---|---|---|
| Acetylsalicylic acid Cmax (ng/mL) AUC0-t (hour·ng/mL) AUC0-inf (hour·ng/mL) | 94.4% (86.0%, 103.5%) 85.1% (81.4%, 89.0%) 85.1% (81.4%, 89.0%) | NA | NA | 94.3% (85.9%, 103.4%) 98.3% (94.0%, 102.7%) 98.2% (94.0%, 102.7%) |
| Salicylic acid Cmax (ng/mL) AUC0-t (hour·ng/mL) AUC0-inf (hour·ng/mL) | 103.7% (100.3%, 107.2%) 91.8% (90.0%, 93.5%) 91.7% (90.0%, 93.5%) | NA | NA | 101.4% (98.0%, 104.8%) 97.9% (96.0%, 99.8%) 97.5% (95.6%, 99.4%) |
| Furosemide Cmax (ng/mL) AUC0-t (hour·ng/mL) AUC0-inf (hour·ng/mL) | 99.5% (89.8%, 110.3%) 91.1% (87.5%, 94.9%) 89.9% (86.5%, 93.5%) | NA | NA | 107.3% (96.8%, 118.9%) 101.3% (97.3%, 105.6%) 99.9% (96.1%, 103.9%) |
| R-Warfarin Cmax (ng/mL) AUC0-t (hour·ng/mL) AUC0-inf (hour·ng/mL) | 105.5% (99.6%, 111.7%) 100.9% (98.2%, 103.7% 100.6% (95.9%, 105.6% | NA | NA | 100.7% (95.1%, 106.7%) 99.7% (97.0%, 102.5%) 99.7% (95.0%, 104.6%) |
| S-Warfarin Cmax (ng/mL) AUC0-t (hour·ng/mL) AUC0-inf (hour·ng/mL) | 107.3% (96.5%, 119.3%) 98.0% (93.5%, 102.6%) 98.5% (93.2%, 104.2%) | NA | NA | 101.5% (91.3%, 113.0%) 98.9% (94.4%, 103.6%) 98.1% (92.8%, 103.8%) |
| Free dabigatran Cmax (ng/mL) AUC0-t (hour·ng/mL) AUC0-inf (hour·ng/mL) | 87.8% (81.3%, 94.8%) 82.4% (77.3%, 87.8%) 82.6% (77.6%, 87.9%) | 93.6% (84.0%, 104.0%) 88.5% (80.3%, 97.6%) 88.5% (80.4%, 97.5%) | 111.0% (103.0%, 120.0%) 94.5% (88.7%, 101.0%) 94.6% (88.9%, 101.0%) | NA |
| Total dabigatran Cmax (ng/mL) AUC0-t (hour·ng/mL) AUC0-inf (hour·ng/mL) | 88.3% (81.5%, 95.7%) 82.4% (77.1%, 88.0%) 82.8% (77.7%, 88.2%) | 95.6% (86.0%, 106.0%) 89.1% (80.9%, 98.1%) 89.2% (81.1%, 98.0%) | 115.0% (107.0%, 125.0%) 97.9% (91.6%, 105.0%) 98.0% (91.9%, 104.0%) | NA |
NA, not applicable.